Merck & Co Company has developed a unique quadruple vaccine for preventing cervical cancer, which is expected to appear in Russia next year.
      
      The vaccine is called “Gardasil” and is recommended for women aged between 9 and 26 as a preventive measure for malignant growths in womb neck, caused by human papilloma virus of types 6, 11, 16 and 18.
      
      Gardasil is not a therapeutic agent, it is designed only for prevention, and thus the most effective way of application for this vaccine is vaccination of girls before they start their sexual life.
      
      In the U.S. Gardasil costs about $360, however its cost in Russia is still unknown. “Gardasil” vaccine is approved for using in European Union, the United States, Canada, Mexico, Brazil, Australia and New Zealand. Its clinical trials have shown 100% protection from HPV of 16 and 18 types.
      
      Two more foreign vaccines for preventing human papilloma virus are now in development.
      
      Source: Commercial Biotechnology